Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All remdesivir studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchRemdesivirRemdesivir (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis       

Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial

Ader et al., Lancet Infectious Diseases, doi:10.1016/S1473-3099(21)00485-0, DISCOVERY, NCT04315948
Sep 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality, day 28 6% Improvement Relative Risk Mortality, day 15 12% 7-point scale 10% 7-point scale (b) -2% Remdesivir  DISCOVERY  LATE TREATMENT  RCT Is late treatment with remdesivir beneficial for COVID-19? RCT 832 patients in multiple countries (March 2020 - January 2021) No significant difference in outcomes seen c19early.org Ader et al., Lancet Infectious Diseases, Sep 2021 Favorsremdesivir Favorscontrol 0 0.5 1 1.5 2+
RCT 857 hospitalized patients, showing no significant differences with remdesivir treatment. EudraCT2020-000936-23.
Gérard, Zhou, Wu, Kamo, Choi, Kim show significantly increased risk of acute kidney injury with remdesivir.
Remdesivir efficacy disappears with longer followup. Mixed-effects meta-regression of efficacy as a function of followup duration across all remdesivir studies shows decreasing efficacy with longer followup7. This may reflect antiviral efficacy being offset by serious adverse effects of treatment.
Followup duration (days) Efficacy Remdesivir mortality efficacy decreases with longer followup 0 15 30 45 60 75 90 105 -25% 0% 25% 50% c19early.org November 2024 mixed-effects meta-regression slope -0.58 [95% CI -0.92 to -0.24] p=0.00089
risk of death, 6.4% lower, RR 0.94, p = 0.77, treatment 34 of 414 (8.2%), control 37 of 418 (8.9%), NNT 156, adjusted per study, odds ratio converted to relative risk, day 28.
risk of death, 11.7% lower, RR 0.88, p = 0.76, treatment 21 of 414 (5.1%), control 24 of 418 (5.7%), NNT 149, day 15.
risk of 7-point scale, 9.9% lower, OR 0.90, p = 0.39, treatment 414, control 418, inverted to make OR<1 favor treatment, 28 days, RR approximated with OR.
risk of 7-point scale, 2.0% higher, OR 1.02, p = 0.85, treatment 414, control 418, inverted to make OR<1 favor treatment, 15 days, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Ader et al., 14 Sep 2021, Randomized Controlled Trial, multiple countries, peer-reviewed, 17 authors, study period 22 March, 2020 - 21 January, 2021, average treatment delay 9.0 days, trial NCT04315948 (history) (DISCOVERY).
This PaperRemdesivirAll
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial
Prof Florence Ader, Maude Bouscambert-Duchamp, Maya Hites, Nathan Peiffer-Smadja, Julien Poissy, Drifa Belhadi, MD Alpha Diallo, Minh-Patrick Lê, Gilles Peytavin, Thérèse Staub, Richard Greil, Jérémie Guedj, Jose-Artur Paiva, PhD Dominique Costagliola, Yazdan Yazdanpanah, Charles Burdet, France Mentré, Alexander Egle, Richard Greil, Michael Joannidis, Bernd Lamprecht, Antoine Altdorfer, Leila Belkhir, Vincent Fraipont, Maya Hites, Gil Verschelden, Jérôme Aboab, Prof Florence Ader, Hafid Ait-Oufella, Claire Andrejak, Pascal Andreu, Laurent Argaud, Firouzé Bani-Sadr, François Benezit, Mathieu Blot, Elisabeth Botelho-Nevers, Lila Bouadma, Olivier Bouchaud, David Bougon, Kevin Bouiller, Fanny Bounes-Vardon, David Boutoille, Alexandre Boyer, Cédric Bruel, André Cabié, Emmanuel Canet, Charles Cazanave, Cyrille Chabartier, Catherine Chirouze, Raphaël Clere-Jehl, Johan Courjon, Flora Crockett, François Danion, Agathe Delbove, Jean Dellamonica, Félix Djossou, Clément Dubost, Alexandre Duvignaud, Olivier Epaulard, Loïc Epelboin, Murielle Fartoukh, Karine Faure, Emmanuel Faure, Tristan Ferry, Cécile Ficko, Samy Figueiredo, Benjamin Gaborit, Rostane Gaci, Amandine Gagneux-Brunon, Sébastien Gallien, Denis Garot, Guillaume Geri, Sébastien Gibot, François Goehringer, Marie Gousseff, Didier Gruson, Yves Hansmann, Olivier Hinschberger, Stéphane Jaureguiberry, Vanessa Jeanmichel, Solen Kerneis, Antoine Kimmoun, Kada Klouche, Marie Lachâtre, Karine Lacombe, Fabrice Laine, Jean-Philippe Lanoix, Odile Launay, Bruno Laviolle, Vincent Le Moing, Jérôme Le Pavec, Yves Le Tulzo, Paul Le Turnier, David Lebeaux, Benjamin Lefevre, Sylvie Leroy, François-Xavier Lescure, Henry Lessire, Benjamin Leveau, Paul Loubet, Alain Makinson, Denis Malvy, Charles-Hugo Marquette, Guillaume Martin-Blondel, Martin Martinot, Julien Mayaux, Armand Mekontso-Dessap, Ferhat Meziani, Jean-Paul Mira, Jean-Michel Molina, Xavier Monnet, Joy Mootien, Bruno Mourvillier, Marlène Murris-Espin, Jean-Christophe Navellou, Saad Nseir, Walid Oulehri, Nathan Peiffer-Smadja, Thomas Perpoint, Gilles Pialoux, Benoît Pilmis, Vincent Piriou, Lionel Piroth, Julien Poissy, Valérie Pourcher, Jean-Pierre Quenot, François Raffi, Jean Reignier, Matthieu Revest, Jean-Christophe Richard, Béatrice Riu-Poulenc, Céline Robert, Pierre-Alexandre Roger, Claire Roger, Elisabeth Rouveix-Nordon, Yvon Ruch, Nadia Saidani, Naomi Sayre, Eric Senneville, Albert Sotto, Francois Stefan, Charles Tacquard, Nicolas Terzi, Julien Textoris, Guillaume Thiery, Jean-François Timsit, Violaine Tolsma, Jean-Marie Turmel, Florent Valour, Florent Wallet, Guilhem Wattecamps, Yazdan Yazdanpanah, Yoann Zerbib, Marc Berna, Jean Reuter, Thérèse Staub, Sandra Braz, Joao-Miguel Ferreira Ribeiro, José-Artur Paiva, Roberto Roncon-Albuquerque, Maude Bouscambert-Duchamp, Alexandre Gaymard, Minh-Patrick Lê, Bruno Lina, Gilles Peytavin, Sarah Tubiana, Sandrine Couffin-Cadièrgues, Hélène Esperou, Drifa Belhadi, Charles Burdet, PhD Dominique Costagliola, Aline Dechanet, Christelle Delmas, MD Alpha Diallo, Claire Fougerou, Jérémie Guedj, France Mentré, Noémie Mercier, Marion Noret, Juliette Saillard, Priyanka Velou
The Lancet Infectious Diseases, doi:10.1016/s1473-3099(21)00485-0
Background The antiviral efficacy of remdesivir against SARS-CoV-2 is still controversial. We aimed to evaluate the clinical efficacy of remdesivir plus standard of care compared with standard of care alone in patients admitted to hospital with COVID-19, with indication of oxygen or ventilator support. Methods DisCoVeRy was a phase 3, open-label, adaptive, multicentre, randomised, controlled trial conducted in 48 sites in Europe (France, Belgium, Austria, Portugal, Luxembourg). Adult patients (aged ≥18 years) admitted to hospital with laboratory-confirmed SARS-CoV-2 infection and illness of any duration were eligible if they had clinical evidence of hypoxaemic pneumonia, or required oxygen supplementation. Exclusion criteria included elevated liver enzymes, severe chronic kidney disease, any contraindication to one of the studied treatments or their use in the 29 days before random assignment, or use of ribavirin, as well as pregnancy or breastfeeding. Participants were randomly assigned (1:1:1:1:1) to receive standard of care alone or in combination with remdesivir, lopinavir-ritonavir, lopinavir-ritonavir and interferon beta-1a, or hydroxychloroquine. Randomisation used computer-generated blocks of various sizes; it was stratified on severity of disease at inclusion and on European administrative region. Remdesivir was administered as 200 mg intravenous infusion on day 1, followed by once daily, 1-h infusions of 100 mg up to 9 days, for a total duration of 10 days. It could be stopped after 5 days if the participant was discharged. The primary outcome was the clinical status at day 15 measured by the WHO seven-point ordinal scale, assessed in the intentionto-treat population. Safety was assessed in the modified intention-to-treat population and was one of the secondary outcomes. This trial is registered with the European Clinical Trials Database, EudraCT2020-000936-23, and ClinicalTrials.gov, NCT04315948. Findings Between March 22 , 2020, and Jan 21 , 2021, 857 participants were enrolled and randomly assigned to remdesivir plus standard of care (n=429) or standard of care only (n=428). 15 participants were excluded from analysis in the remdesivir group, and ten in the control group. At day 15, the distribution of the WHO ordinal scale was: (1) not hospitalised, no limitations on activities (61 [15%] of 414 in the remdesivir group vs 73 [17%] of 418 in the control group); (2) not hospitalised, limitation on activities (129 [31%] vs 132 [32%]); (3) hospitalised, not requiring supplemental oxygen (50 [12%] vs 29 [7%]); (4) hospitalised, requiring supplemental oxygen (76 [18%] vs 67 [16%]); (5) hospitalised, on non-invasive ventilation or high flow oxygen devices (15 [4%] vs 14 [3%]); (6) hospitalised, on invasive mechanical ventilation or extracorporeal membrane oxygenation (62 [15%] vs 79 [19%]); (7) death (21 [5%] vs 24 [6%]). The difference between treatment groups was not significant (odds ratio 0•98 [95% CI 0•77-1•25]; p=0•85). There was no..
Contributors FA, NP-S, JP, MB-D, GP, TS, RG, J-AP, DC, YY, CB, and FM were involved in the design, establishment, and day-to-day management and implementation of the trial. FA, MH, TS, RG, J-AP, DC, YY, and FM obtained funding for the trial. FA, MH, NP-S, JP, TS, RG, and J-AP included participants in the trial. MB-D was responsible for the virological analyses. M-PL and GP were responsible for the pharmacological analyses. FA, MB-D, DB, AD, M-PL, GP, CB, and FM were in charge of data curation and accessed and verified the data. DB, JG, DC, CB, and FM were involved in the statistical analyses. FA, MB-D, DB, AD, MH, JG, CB, and FM wrote the original draft of the manuscript, which was reviewed and edited by NP-S, JP, MPL, GP, DC, and YY. All authors contributed to refinement of and approved this manuscript. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication. Declaration of interests DC reports grants and lecture fees from Janssen and lecture fees from Gilead, outside the submitted work. FM reports grants and consulting fees from Da Volterra, grants from Sanofi, and consulting fees from Ipsen, outside the submitted work. MH reports grants from The Belgian Center for Knowledge (KCE), the Fonds Erasme-COVID-Université Libre de Bruxelles and the EU-Horizon programme, for the submitted work; and has received support for attending meetings from Pfizer; support for participation on an advisory board for..
References
Ader, Peiffer-Smadja, Poissy, An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19, Clin Microbiol Infect, doi:10.1016/j.cmi.2021.05.020
Ader, Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults, BMJ Open
Avataneo, De Nicolò, Cusato, Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease, J Antimicrob Chemother
Barratt-Due, Olsen, Nezvalova-Henriksen, Evaluation of the effects of remdesivir and hydroxychloroquine on viral clearance in COVID-19: a randomized trial, Ann Intern Med, doi:10.7326/M21-0653
Beigel, Tomashek, Dodd, Remdesivir for the treatment of COVID-19-final report, N Engl J Med
Dougan, Nirula, Azizad, Bamlanivimab plus etesevimab in mild or moderate COVID-19, N Engl J Med, doi:10.1056/NEJMoa2102685
Etievant, Bal, Escuret, Performance assessment of SARS-CoV-2 PCR assays developed by WHO referral laboratories, J Clin Med
Gonçalves, Bertrand, Ke, Timing of antiviral treatment initiation is critical to reduce SARS-CoV-2 viral load, CPT Pharmacometrics Syst Pharmacol
Gottlieb, Nirula, Chen, Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial, JAMA
Horby, Lim, Emberson, Dexamethasone in hospitalized patients with COVID-19, N Engl J Med
Humeniuk, Mathias, Cao, Safety, tolerability, and pharmacokinetics of remdesivir, an antiviral for treatment of COVID-19, in healthy subjects, Clin Transl Sci
Humeniuk, Mathias, Kirby, Pharmacokinetic, pharmacodynamic, and drug-interaction profile of remdesivir, a SARS-CoV-2 replication inhibitor, Clin Pharmacokinet
Libster, Marc, Wappner, Early high-titer plasma therapy to prevent severe COVID-19 in older adults, N Engl J Med
Lê, Hingrat, Jaquet, Removal of remdesivir's metabolite GS-441524 by hemodialysis in a double lung transplant recipient with COVID-19, Antimicrob Agents Chemother
Nicholson, Aoki, Osterhaus, Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial, Lancet
Néant, Lingas, Hingrat, Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort, Proc Natl Acad Sci
Pan, Peto, Henao-Restrepo, Repurposed antiviral drugs for COVID-19-interim WHO Solidarity trial results, N Engl J Med
Paranjpe, Fuster, Lala, Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19, J Am Coll Cardiol
Rasmussen, Popescu, SARS-CoV-2 transmission without symptoms, Science
Sterne, Murthy, Diaz, Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis, JAMA
Tang, Bai, Chen, Gong, Li et al., Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy, J Thromb Haemost
Villar, Ferrando, Martínez, Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial, Lancet Respir Med
Wang, Cao, Zhang, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res
Wang, Zhang, Du, Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial, Lancet
Warren, Jordan, Lo, Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys, Nature
Weinreich, Sivapalasingam, Norton, REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19, N Engl J Med
Williamson, Feldmann, Schwarz, Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2, Nature
{ 'indexed': {'date-parts': [[2024, 4, 9]], 'date-time': '2024-04-09T06:32:10Z', 'timestamp': 1712644330124}, 'reference-count': 27, 'publisher': 'Elsevier BV', 'issue': '2', 'license': [ { 'start': { 'date-parts': [[2022, 2, 1]], 'date-time': '2022-02-01T00:00:00Z', 'timestamp': 1643673600000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}, { 'start': { 'date-parts': [[2022, 7, 28]], 'date-time': '2022-07-28T00:00:00Z', 'timestamp': 1658966400000}, 'content-version': 'am', 'delay-in-days': 177, 'URL': 'http://www.elsevier.com/open-access/userlicense/1.0/'}, { 'start': { 'date-parts': [[2022, 2, 1]], 'date-time': '2022-02-01T00:00:00Z', 'timestamp': 1643673600000}, 'content-version': 'stm-asf', 'delay-in-days': 0, 'URL': 'https://doi.org/10.15223/policy-017'}, { 'start': { 'date-parts': [[2022, 2, 1]], 'date-time': '2022-02-01T00:00:00Z', 'timestamp': 1643673600000}, 'content-version': 'stm-asf', 'delay-in-days': 0, 'URL': 'https://doi.org/10.15223/policy-037'}, { 'start': { 'date-parts': [[2022, 2, 1]], 'date-time': '2022-02-01T00:00:00Z', 'timestamp': 1643673600000}, 'content-version': 'stm-asf', 'delay-in-days': 0, 'URL': 'https://doi.org/10.15223/policy-012'}, { 'start': { 'date-parts': [[2022, 2, 1]], 'date-time': '2022-02-01T00:00:00Z', 'timestamp': 1643673600000}, 'content-version': 'stm-asf', 'delay-in-days': 0, 'URL': 'https://doi.org/10.15223/policy-029'}, { 'start': { 'date-parts': [[2022, 2, 1]], 'date-time': '2022-02-01T00:00:00Z', 'timestamp': 1643673600000}, 'content-version': 'stm-asf', 'delay-in-days': 0, 'URL': 'https://doi.org/10.15223/policy-004'}], 'funder': [ {'DOI': '10.13039/100015400', 'name': 'Fonds Erasme', 'doi-asserted-by': 'publisher'}, {'DOI': '10.13039/501100000780', 'name': 'European Commission', 'doi-asserted-by': 'publisher'}, { 'DOI': '10.13039/501100008530', 'name': 'European Regional Development Fund', 'doi-asserted-by': 'publisher'}, {'DOI': '10.13039/501100009242', 'name': 'DGOS', 'doi-asserted-by': 'publisher'}, { 'DOI': '10.13039/501100019353', 'name': 'Belgian Health Care Knowledge Centre', 'doi-asserted-by': 'publisher'}], 'content-domain': { 'domain': [ 'clinicalkey.fr', 'clinicalkey.jp', 'clinicalkey.es', 'clinicalkey.com.au', 'clinicalkey.com', 'em-consulte.com', 'thelancet.com', 'elsevier.com', 'sciencedirect.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2022, 2]]}, 'DOI': '10.1016/s1473-3099(21)00485-0', 'type': 'journal-article', 'created': {'date-parts': [[2021, 9, 14]], 'date-time': '2021-09-14T22:31:01Z', 'timestamp': 1631658661000}, 'page': '209-221', 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy', 'source': 'Crossref', 'is-referenced-by-count': 211, 'title': 'Remdesivir plus standard of care versus standard of care alone for the treatment of patients ' 'admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label ' 'trial', 'prefix': '10.1016', 'volume': '22', 'author': [ {'given': 'Florence', 'family': 'Ader', 'sequence': 'first', 'affiliation': []}, { 'given': 'Maude', 'family': 'Bouscambert-Duchamp', 'sequence': 'additional', 'affiliation': []}, {'given': 'Maya', 'family': 'Hites', 'sequence': 'additional', 'affiliation': []}, {'given': 'Nathan', 'family': 'Peiffer-Smadja', 'sequence': 'additional', 'affiliation': []}, {'given': 'Julien', 'family': 'Poissy', 'sequence': 'additional', 'affiliation': []}, {'given': 'Drifa', 'family': 'Belhadi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Alpha', 'family': 'Diallo', 'sequence': 'additional', 'affiliation': []}, {'given': 'Minh-Patrick', 'family': 'Lê', 'sequence': 'additional', 'affiliation': []}, {'given': 'Gilles', 'family': 'Peytavin', 'sequence': 'additional', 'affiliation': []}, {'given': 'Thérèse', 'family': 'Staub', 'sequence': 'additional', 'affiliation': []}, {'given': 'Richard', 'family': 'Greil', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jérémie', 'family': 'Guedj', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jose-Artur', 'family': 'Paiva', 'sequence': 'additional', 'affiliation': []}, {'given': 'Dominique', 'family': 'Costagliola', 'sequence': 'additional', 'affiliation': []}, {'given': 'Yazdan', 'family': 'Yazdanpanah', 'sequence': 'additional', 'affiliation': []}, {'given': 'Charles', 'family': 'Burdet', 'sequence': 'additional', 'affiliation': []}, {'given': 'France', 'family': 'Mentré', 'sequence': 'additional', 'affiliation': []}, {'given': 'Alexander', 'family': 'Egle', 'sequence': 'additional', 'affiliation': []}, {'given': 'Richard', 'family': 'Greil', 'sequence': 'additional', 'affiliation': []}, {'given': 'Michael', 'family': 'Joannidis', 'sequence': 'additional', 'affiliation': []}, {'given': 'Bernd', 'family': 'Lamprecht', 'sequence': 'additional', 'affiliation': []}, {'given': 'Antoine', 'family': 'Altdorfer', 'sequence': 'additional', 'affiliation': []}, {'given': 'Leila', 'family': 'Belkhir', 'sequence': 'additional', 'affiliation': []}, {'given': 'Vincent', 'family': 'Fraipont', 'sequence': 'additional', 'affiliation': []}, {'given': 'Maya', 'family': 'Hites', 'sequence': 'additional', 'affiliation': []}, {'given': 'Gil', 'family': 'Verschelden', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jérôme', 'family': 'Aboab', 'sequence': 'additional', 'affiliation': []}, {'given': 'Florence', 'family': 'Ader', 'sequence': 'additional', 'affiliation': []}, {'given': 'Hafid', 'family': 'Ait-Oufella', 'sequence': 'additional', 'affiliation': []}, {'given': 'Claire', 'family': 'Andrejak', 'sequence': 'additional', 'affiliation': []}, {'given': 'Pascal', 'family': 'Andreu', 'sequence': 'additional', 'affiliation': []}, {'given': 'Laurent', 'family': 'Argaud', 'sequence': 'additional', 'affiliation': []}, {'given': 'Firouzé', 'family': 'Bani-Sadr', 'sequence': 'additional', 'affiliation': []}, {'given': 'François', 'family': 'Benezit', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mathieu', 'family': 'Blot', 'sequence': 'additional', 'affiliation': []}, {'given': 'Elisabeth', 'family': 'Botelho-Nevers', 'sequence': 'additional', 'affiliation': []}, {'given': 'Lila', 'family': 'Bouadma', 'sequence': 'additional', 'affiliation': []}, {'given': 'Olivier', 'family': 'Bouchaud', 'sequence': 'additional', 'affiliation': []}, {'given': 'David', 'family': 'Bougon', 'sequence': 'additional', 'affiliation': []}, {'given': 'Kevin', 'family': 'Bouiller', 'sequence': 'additional', 'affiliation': []}, {'given': 'Fanny', 'family': 'Bounes-Vardon', 'sequence': 'additional', 'affiliation': []}, {'given': 'David', 'family': 'Boutoille', 'sequence': 'additional', 'affiliation': []}, {'given': 'Alexandre', 'family': 'Boyer', 'sequence': 'additional', 'affiliation': []}, {'given': 'Cédric', 'family': 'Bruel', 'sequence': 'additional', 'affiliation': []}, {'given': 'André', 'family': 'Cabié', 'sequence': 'additional', 'affiliation': []}, {'given': 'Emmanuel', 'family': 'Canet', 'sequence': 'additional', 'affiliation': []}, {'given': 'Charles', 'family': 'Cazanave', 'sequence': 'additional', 'affiliation': []}, {'given': 'Cyrille', 'family': 'Chabartier', 'sequence': 'additional', 'affiliation': []}, {'given': 'Catherine', 'family': 'Chirouze', 'sequence': 'additional', 'affiliation': []}, {'given': 'Raphaël', 'family': 'Clere-Jehl', 'sequence': 'additional', 'affiliation': []}, {'given': 'Johan', 'family': 'Courjon', 'sequence': 'additional', 'affiliation': []}, {'given': 'Flora', 'family': 'Crockett', 'sequence': 'additional', 'affiliation': []}, {'given': 'François', 'family': 'Danion', 'sequence': 'additional', 'affiliation': []}, {'given': 'Agathe', 'family': 'Delbove', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jean', 'family': 'Dellamonica', 'sequence': 'additional', 'affiliation': []}, {'given': 'Félix', 'family': 'Djossou', 'sequence': 'additional', 'affiliation': []}, {'given': 'Clément', 'family': 'Dubost', 'sequence': 'additional', 'affiliation': []}, {'given': 'Alexandre', 'family': 'Duvignaud', 'sequence': 'additional', 'affiliation': []}, {'given': 'Olivier', 'family': 'Epaulard', 'sequence': 'additional', 'affiliation': []}, {'given': 'Loïc', 'family': 'Epelboin', 'sequence': 'additional', 'affiliation': []}, {'given': 'Murielle', 'family': 'Fartoukh', 'sequence': 'additional', 'affiliation': []}, {'given': 'Karine', 'family': 'Faure', 'sequence': 'additional', 'affiliation': []}, {'given': 'Emmanuel', 'family': 'Faure', 'sequence': 'additional', 'affiliation': []}, {'given': 'Tristan', 'family': 'Ferry', 'sequence': 'additional', 'affiliation': []}, {'given': 'Cécile', 'family': 'Ficko', 'sequence': 'additional', 'affiliation': []}, {'given': 'Samy', 'family': 'Figueiredo', 'sequence': 'additional', 'affiliation': []}, {'given': 'Benjamin', 'family': 'Gaborit', 'sequence': 'additional', 'affiliation': []}, {'given': 'Rostane', 'family': 'Gaci', 'sequence': 'additional', 'affiliation': []}, {'given': 'Amandine', 'family': 'Gagneux-Brunon', 'sequence': 'additional', 'affiliation': []}, {'given': 'Sébastien', 'family': 'Gallien', 'sequence': 'additional', 'affiliation': []}, {'given': 'Denis', 'family': 'Garot', 'sequence': 'additional', 'affiliation': []}, {'given': 'Guillaume', 'family': 'Geri', 'sequence': 'additional', 'affiliation': []}, {'given': 'Sébastien', 'family': 'Gibot', 'sequence': 'additional', 'affiliation': []}, {'given': 'François', 'family': 'Goehringer', 'sequence': 'additional', 'affiliation': []}, {'given': 'Marie', 'family': 'Gousseff', 'sequence': 'additional', 'affiliation': []}, {'given': 'Didier', 'family': 'Gruson', 'sequence': 'additional', 'affiliation': []}, {'given': 'Yves', 'family': 'Hansmann', 'sequence': 'additional', 'affiliation': []}, {'given': 'Olivier', 'family': 'Hinschberger', 'sequence': 'additional', 'affiliation': []}, {'given': 'Stéphane', 'family': 'Jaureguiberry', 'sequence': 'additional', 'affiliation': []}, {'given': 'Vanessa', 'family': 'Jeanmichel', 'sequence': 'additional', 'affiliation': []}, {'given': 'Solen', 'family': 'Kerneis', 'sequence': 'additional', 'affiliation': []}, {'given': 'Antoine', 'family': 'Kimmoun', 'sequence': 'additional', 'affiliation': []}, {'given': 'Kada', 'family': 'Klouche', 'sequence': 'additional', 'affiliation': []}, {'given': 'Marie', 'family': 'Lachâtre', 'sequence': 'additional', 'affiliation': []}, {'given': 'Karine', 'family': 'Lacombe', 'sequence': 'additional', 'affiliation': []}, {'given': 'Fabrice', 'family': 'Laine', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jean-Philippe', 'family': 'Lanoix', 'sequence': 'additional', 'affiliation': []}, {'given': 'Odile', 'family': 'Launay', 'sequence': 'additional', 'affiliation': []}, {'given': 'Bruno', 'family': 'Laviolle', 'sequence': 'additional', 'affiliation': []}, {'given': 'Vincent', 'family': 'Le Moing', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jérôme', 'family': 'Le Pavec', 'sequence': 'additional', 'affiliation': []}, {'given': 'Yves', 'family': 'Le Tulzo', 'sequence': 'additional', 'affiliation': []}, {'given': 'Paul', 'family': 'Le Turnier', 'sequence': 'additional', 'affiliation': []}, {'given': 'David', 'family': 'Lebeaux', 'sequence': 'additional', 'affiliation': []}, {'given': 'Benjamin', 'family': 'Lefevre', 'sequence': 'additional', 'affiliation': []}, {'given': 'Sylvie', 'family': 'Leroy', 'sequence': 'additional', 'affiliation': []}, {'given': 'François-Xavier', 'family': 'Lescure', 'sequence': 'additional', 'affiliation': []}, {'given': 'Henry', 'family': 'Lessire', 'sequence': 'additional', 'affiliation': []}, {'given': 'Benjamin', 'family': 'Leveau', 'sequence': 'additional', 'affiliation': []}, {'given': 'Paul', 'family': 'Loubet', 'sequence': 'additional', 'affiliation': []}, {'given': 'Alain', 'family': 'Makinson', 'sequence': 'additional', 'affiliation': []}, {'given': 'Denis', 'family': 'Malvy', 'sequence': 'additional', 'affiliation': []}, {'given': 'Charles-Hugo', 'family': 'Marquette', 'sequence': 'additional', 'affiliation': []}, {'given': 'Guillaume', 'family': 'Martin-Blondel', 'sequence': 'additional', 'affiliation': []}, {'given': 'Martin', 'family': 'Martinot', 'sequence': 'additional', 'affiliation': []}, {'given': 'Julien', 'family': 'Mayaux', 'sequence': 'additional', 'affiliation': []}, {'given': 'Armand', 'family': 'Mekontso-Dessap', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ferhat', 'family': 'Meziani', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jean-Paul', 'family': 'Mira', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jean-Michel', 'family': 'Molina', 'sequence': 'additional', 'affiliation': []}, {'given': 'Xavier', 'family': 'Monnet', 'sequence': 'additional', 'affiliation': []}, {'given': 'Joy', 'family': 'Mootien', 'sequence': 'additional', 'affiliation': []}, {'given': 'Bruno', 'family': 'Mourvillier', 'sequence': 'additional', 'affiliation': []}, {'given': 'Marlène', 'family': 'Murris-Espin', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jean-Christophe', 'family': 'Navellou', 'sequence': 'additional', 'affiliation': []}, {'given': 'Saad', 'family': 'Nseir', 'sequence': 'additional', 'affiliation': []}, {'given': 'Walid', 'family': 'Oulehri', 'sequence': 'additional', 'affiliation': []}, {'given': 'Nathan', 'family': 'Peiffer-Smadja', 'sequence': 'additional', 'affiliation': []}, {'given': 'Thomas', 'family': 'Perpoint', 'sequence': 'additional', 'affiliation': []}, {'given': 'Gilles', 'family': 'Pialoux', 'sequence': 'additional', 'affiliation': []}, {'given': 'Benoît', 'family': 'Pilmis', 'sequence': 'additional', 'affiliation': []}, {'given': 'Vincent', 'family': 'Piriou', 'sequence': 'additional', 'affiliation': []}, {'given': 'Lionel', 'family': 'Piroth', 'sequence': 'additional', 'affiliation': []}, {'given': 'Julien', 'family': 'Poissy', 'sequence': 'additional', 'affiliation': []}, {'given': 'Valérie', 'family': 'Pourcher', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jean-Pierre', 'family': 'Quenot', 'sequence': 'additional', 'affiliation': []}, {'given': 'François', 'family': 'Raffi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jean', 'family': 'Reignier', 'sequence': 'additional', 'affiliation': []}, {'given': 'Matthieu', 'family': 'Revest', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jean-Christophe', 'family': 'Richard', 'sequence': 'additional', 'affiliation': []}, {'given': 'Béatrice', 'family': 'Riu-Poulenc', 'sequence': 'additional', 'affiliation': []}, {'given': 'Céline', 'family': 'Robert', 'sequence': 'additional', 'affiliation': []}, {'given': 'Pierre-Alexandre', 'family': 'Roger', 'sequence': 'additional', 'affiliation': []}, {'given': 'Claire', 'family': 'Roger', 'sequence': 'additional', 'affiliation': []}, {'given': 'Elisabeth', 'family': 'Rouveix-Nordon', 'sequence': 'additional', 'affiliation': []}, {'given': 'Yvon', 'family': 'Ruch', 'sequence': 'additional', 'affiliation': []}, {'given': 'Nadia', 'family': 'Saidani', 'sequence': 'additional', 'affiliation': []}, {'given': 'Naomi', 'family': 'Sayre', 'sequence': 'additional', 'affiliation': []}, {'given': 'Eric', 'family': 'Senneville', 'sequence': 'additional', 'affiliation': []}, {'given': 'Albert', 'family': 'Sotto', 'sequence': 'additional', 'affiliation': []}, {'given': 'Francois', 'family': 'Stefan', 'sequence': 'additional', 'affiliation': []}, {'given': 'Charles', 'family': 'Tacquard', 'sequence': 'additional', 'affiliation': []}, {'given': 'Nicolas', 'family': 'Terzi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Julien', 'family': 'Textoris', 'sequence': 'additional', 'affiliation': []}, {'given': 'Guillaume', 'family': 'Thiery', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jean-François', 'family': 'Timsit', 'sequence': 'additional', 'affiliation': []}, {'given': 'Violaine', 'family': 'Tolsma', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jean-Marie', 'family': 'Turmel', 'sequence': 'additional', 'affiliation': []}, {'given': 'Florent', 'family': 'Valour', 'sequence': 'additional', 'affiliation': []}, {'given': 'Florent', 'family': 'Wallet', 'sequence': 'additional', 'affiliation': []}, {'given': 'Guilhem', 'family': 'Wattecamps', 'sequence': 'additional', 'affiliation': []}, {'given': 'Yazdan', 'family': 'Yazdanpanah', 'sequence': 'additional', 'affiliation': []}, {'given': 'Yoann', 'family': 'Zerbib', 'sequence': 'additional', 'affiliation': []}, {'given': 'Marc', 'family': 'Berna', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jean', 'family': 'Reuter', 'sequence': 'additional', 'affiliation': []}, {'given': 'Thérèse', 'family': 'Staub', 'sequence': 'additional', 'affiliation': []}, {'given': 'Sandra', 'family': 'Braz', 'sequence': 'additional', 'affiliation': []}, { 'given': 'Joao-Miguel', 'family': 'Ferreira Ribeiro', 'sequence': 'additional', 'affiliation': []}, {'given': 'José-Artur', 'family': 'Paiva', 'sequence': 'additional', 'affiliation': []}, { 'given': 'Roberto', 'family': 'Roncon-Albuquerque', 'sequence': 'additional', 'affiliation': []}, { 'given': 'Maude', 'family': 'Bouscambert-Duchamp', 'sequence': 'additional', 'affiliation': []}, {'given': 'Alexandre', 'family': 'Gaymard', 'sequence': 'additional', 'affiliation': []}, {'given': 'Minh-Patrick', 'family': 'Lê', 'sequence': 'additional', 'affiliation': []}, {'given': 'Bruno', 'family': 'Lina', 'sequence': 'additional', 'affiliation': []}, {'given': 'Gilles', 'family': 'Peytavin', 'sequence': 'additional', 'affiliation': []}, {'given': 'Sarah', 'family': 'Tubiana', 'sequence': 'additional', 'affiliation': []}, { 'given': 'Sandrine', 'family': 'Couffin-Cadièrgues', 'sequence': 'additional', 'affiliation': []}, {'given': 'Hélène', 'family': 'Esperou', 'sequence': 'additional', 'affiliation': []}, {'given': 'Drifa', 'family': 'Belhadi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Charles', 'family': 'Burdet', 'sequence': 'additional', 'affiliation': []}, {'given': 'Dominique', 'family': 'Costagliola', 'sequence': 'additional', 'affiliation': []}, {'given': 'Aline', 'family': 'Dechanet', 'sequence': 'additional', 'affiliation': []}, {'given': 'Christelle', 'family': 'Delmas', 'sequence': 'additional', 'affiliation': []}, {'given': 'Alpha', 'family': 'Diallo', 'sequence': 'additional', 'affiliation': []}, {'given': 'Claire', 'family': 'Fougerou', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jérémie', 'family': 'Guedj', 'sequence': 'additional', 'affiliation': []}, {'given': 'France', 'family': 'Mentré', 'sequence': 'additional', 'affiliation': []}, {'given': 'Noémie', 'family': 'Mercier', 'sequence': 'additional', 'affiliation': []}, {'given': 'Marion', 'family': 'Noret', 'sequence': 'additional', 'affiliation': []}, {'given': 'Juliette', 'family': 'Saillard', 'sequence': 'additional', 'affiliation': []}, {'given': 'Priyanka', 'family': 'Velou', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'key': '10.1016/S1473-3099(21)00485-0_bib1', 'doi-asserted-by': 'crossref', 'DOI': '10.1136/bmjopen-2020-041437', 'article-title': 'Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised ' 'trial of the safety and efficacy of treatments for COVID-19 in ' 'hospitalised adults', 'volume': '10', 'author': 'Ader', 'year': '2020', 'journal-title': 'BMJ Open'}, { 'key': '10.1016/S1473-3099(21)00485-0_bib2', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.cmi.2021.05.020', 'article-title': 'An open-label randomized controlled trial of the effect of ' 'lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and ' 'hydroxychloroquine in hospitalized patients with COVID-19', 'author': 'Ader', 'year': '2021', 'journal-title': 'Clin Microbiol Infect'}, { 'key': '10.1016/S1473-3099(21)00485-0_bib3', 'doi-asserted-by': 'crossref', 'first-page': 'e01521', 'DOI': '10.1128/AAC.01521-20', 'article-title': "Removal of remdesivir's metabolite GS-441524 by hemodialysis in a " 'double lung transplant recipient with COVID-19', 'volume': '64', 'author': 'Lê', 'year': '2020', 'journal-title': 'Antimicrob Agents Chemother'}, { 'key': '10.1016/S1473-3099(21)00485-0_bib5', 'doi-asserted-by': 'crossref', 'first-page': '381', 'DOI': '10.1038/nature17180', 'article-title': 'Therapeutic efficacy of the small molecule GS-5734 against Ebola virus ' 'in rhesus monkeys', 'volume': '531', 'author': 'Warren', 'year': '2016', 'journal-title': 'Nature'}, { 'key': '10.1016/S1473-3099(21)00485-0_bib6', 'doi-asserted-by': 'crossref', 'first-page': '269', 'DOI': '10.1038/s41422-020-0282-0', 'article-title': 'Remdesivir and chloroquine effectively inhibit the recently emerged ' 'novel coronavirus (2019-nCoV) in vitro', 'volume': '30', 'author': 'Wang', 'year': '2020', 'journal-title': 'Cell Res'}, { 'key': '10.1016/S1473-3099(21)00485-0_bib7', 'doi-asserted-by': 'crossref', 'first-page': '273', 'DOI': '10.1038/s41586-020-2423-5', 'article-title': 'Clinical benefit of remdesivir in rhesus macaques infected with ' 'SARS-CoV-2', 'volume': '585', 'author': 'Williamson', 'year': '2020', 'journal-title': 'Nature'}, { 'key': '10.1016/S1473-3099(21)00485-0_bib8', 'doi-asserted-by': 'crossref', 'first-page': '1569', 'DOI': '10.1016/S0140-6736(20)31022-9', 'article-title': 'Remdesivir in adults with severe COVID-19: a randomised, double-blind, ' 'placebo-controlled, multicentre trial', 'volume': '395', 'author': 'Wang', 'year': '2020', 'journal-title': 'Lancet'}, { 'key': '10.1016/S1473-3099(21)00485-0_bib9', 'doi-asserted-by': 'crossref', 'first-page': '1813', 'DOI': '10.1056/NEJMoa2007764', 'article-title': 'Remdesivir for the treatment of COVID-19—final report', 'volume': '383', 'author': 'Beigel', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/S1473-3099(21)00485-0_bib10', 'doi-asserted-by': 'crossref', 'first-page': '497', 'DOI': '10.1056/NEJMoa2023184', 'article-title': 'Repurposed antiviral drugs for COVID-19—interim WHO Solidarity trial ' 'results', 'volume': '384', 'author': 'Pan', 'year': '2021', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/S1473-3099(21)00485-0_bib11', 'doi-asserted-by': 'crossref', 'first-page': '693', 'DOI': '10.1056/NEJMoa2021436', 'article-title': 'Dexamethasone in hospitalized patients with COVID-19', 'volume': '384', 'author': 'Horby', 'year': '2021', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/S1473-3099(21)00485-0_bib12', 'doi-asserted-by': 'crossref', 'first-page': '1330', 'DOI': '10.1001/jama.2020.17023', 'article-title': 'Association between administration of systemic corticosteroids and ' 'mortality among critically ill patients with COVID-19: a meta-analysis', 'volume': '324', 'author': 'Sterne', 'year': '2020', 'journal-title': 'JAMA'}, { 'key': '10.1016/S1473-3099(21)00485-0_bib13', 'doi-asserted-by': 'crossref', 'first-page': '267', 'DOI': '10.1016/S2213-2600(19)30417-5', 'article-title': 'Dexamethasone treatment for the acute respiratory distress syndrome: a ' 'multicentre, randomised controlled trial', 'volume': '8', 'author': 'Villar', 'year': '2020', 'journal-title': 'Lancet Respir Med'}, { 'key': '10.1016/S1473-3099(21)00485-0_bib14', 'doi-asserted-by': 'crossref', 'first-page': '1094', 'DOI': '10.1111/jth.14817', 'article-title': 'Anticoagulant treatment is associated with decreased mortality in ' 'severe coronavirus disease 2019 patients with coagulopathy', 'volume': '18', 'author': 'Tang', 'year': '2020', 'journal-title': 'J Thromb Haemost'}, { 'key': '10.1016/S1473-3099(21)00485-0_bib15', 'doi-asserted-by': 'crossref', 'first-page': '122', 'DOI': '10.1016/j.jacc.2020.05.001', 'article-title': 'Association of treatment dose anticoagulation with in-hospital survival ' 'among hospitalized patients with COVID-19', 'volume': '76', 'author': 'Paranjpe', 'year': '2020', 'journal-title': 'J Am Coll Cardiol'}, { 'key': '10.1016/S1473-3099(21)00485-0_bib16', 'doi-asserted-by': 'crossref', 'DOI': '10.3390/jcm9061871', 'article-title': 'Performance assessment of SARS-CoV-2 PCR assays developed by WHO ' 'referral laboratories', 'volume': '9', 'author': 'Etievant', 'year': '2020', 'journal-title': 'J Clin Med'}, { 'key': '10.1016/S1473-3099(21)00485-0_bib17', 'doi-asserted-by': 'crossref', 'first-page': '1772', 'DOI': '10.1093/jac/dkaa152', 'article-title': 'Development and validation of a UHPLC-MS/MS method for quantification ' 'of the prodrug remdesivir and its metabolite GS-441524: a tool for ' 'clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus ' 'disease', 'volume': '75', 'author': 'Avataneo', 'year': '2020', 'journal-title': 'J Antimicrob Chemother'}, { 'key': '10.1016/S1473-3099(21)00485-0_bib18', 'doi-asserted-by': 'crossref', 'DOI': '10.7326/M21-0653', 'article-title': 'Evaluation of the effects of remdesivir and hydroxychloroquine on viral ' 'clearance in COVID-19: a randomized trial', 'author': 'Barratt-Due', 'year': '2021', 'journal-title': 'Ann Intern Med'}, { 'key': '10.1016/S1473-3099(21)00485-0_bib19', 'doi-asserted-by': 'crossref', 'first-page': '509', 'DOI': '10.1002/psp4.12543', 'article-title': 'Timing of antiviral treatment initiation is critical to reduce ' 'SARS-CoV-2 viral load', 'volume': '9', 'author': 'Gonçalves', 'year': '2020', 'journal-title': 'CPT Pharmacometrics Syst Pharmacol'}, { 'key': '10.1016/S1473-3099(21)00485-0_bib20', 'doi-asserted-by': 'crossref', 'DOI': '10.1073/pnas.2017962118', 'article-title': 'Modeling SARS-CoV-2 viral kinetics and association with mortality in ' 'hospitalized patients from the French COVID cohort', 'volume': '118', 'author': 'Néant', 'year': '2021', 'journal-title': 'Proc Natl Acad Sci USA'}, { 'key': '10.1016/S1473-3099(21)00485-0_bib21', 'doi-asserted-by': 'crossref', 'first-page': '1206', 'DOI': '10.1126/science.abf9569', 'article-title': 'SARS-CoV-2 transmission without symptoms', 'volume': '371', 'author': 'Rasmussen', 'year': '2021', 'journal-title': 'Science'}, { 'key': '10.1016/S1473-3099(21)00485-0_bib22', 'doi-asserted-by': 'crossref', 'first-page': '1845', 'DOI': '10.1016/S0140-6736(00)02288-1', 'article-title': 'Efficacy and safety of oseltamivir in treatment of acute influenza: a ' 'randomised controlled trial', 'volume': '355', 'author': 'Nicholson', 'year': '2000', 'journal-title': 'Lancet'}, { 'key': '10.1016/S1473-3099(21)00485-0_bib23', 'doi-asserted-by': 'crossref', 'first-page': '632', 'DOI': '10.1001/jama.2021.0202', 'article-title': 'Effect of bamlanivimab as monotherapy or in combination with etesevimab ' 'on viral load in patients with mild to moderate COVID-19: a randomized ' 'clinical trial', 'volume': '325', 'author': 'Gottlieb', 'year': '2021', 'journal-title': 'JAMA'}, { 'key': '10.1016/S1473-3099(21)00485-0_bib24', 'doi-asserted-by': 'crossref', 'first-page': '610', 'DOI': '10.1056/NEJMoa2033700', 'article-title': 'Early high-titer plasma therapy to prevent severe COVID-19 in older ' 'adults', 'volume': '384', 'author': 'Libster', 'year': '2021', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/S1473-3099(21)00485-0_bib25', 'doi-asserted-by': 'crossref', 'DOI': '10.1056/NEJMoa2102685', 'article-title': 'Bamlanivimab plus etesevimab in mild or moderate COVID-19', 'author': 'Dougan', 'year': '2021', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/S1473-3099(21)00485-0_bib26', 'doi-asserted-by': 'crossref', 'first-page': '238', 'DOI': '10.1056/NEJMoa2035002', 'article-title': 'REGN-COV2, a neutralizing antibody cocktail, in outpatients with ' 'COVID-19', 'volume': '384', 'author': 'Weinreich', 'year': '2021', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/S1473-3099(21)00485-0_bib27', 'doi-asserted-by': 'crossref', 'first-page': '896', 'DOI': '10.1111/cts.12840', 'article-title': 'Safety, tolerability, and pharmacokinetics of remdesivir, an antiviral ' 'for treatment of COVID-19, in healthy subjects', 'volume': '13', 'author': 'Humeniuk', 'year': '2020', 'journal-title': 'Clin Transl Sci'}, { 'key': '10.1016/S1473-3099(21)00485-0_bib28', 'doi-asserted-by': 'crossref', 'first-page': '569', 'DOI': '10.1007/s40262-021-00984-5', 'article-title': 'Pharmacokinetic, pharmacodynamic, and drug-interaction profile of ' 'remdesivir, a SARS-CoV-2 replication inhibitor', 'volume': '60', 'author': 'Humeniuk', 'year': '2021', 'journal-title': 'Clin Pharmacokinet'}], 'container-title': 'The Lancet Infectious Diseases', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S1473309921004850?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S1473309921004850?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2023, 11, 8]], 'date-time': '2023-11-08T20:15:40Z', 'timestamp': 1699474540000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S1473309921004850'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 2]]}, 'references-count': 27, 'journal-issue': {'issue': '2', 'published-print': {'date-parts': [[2022, 2]]}}, 'alternative-id': ['S1473309921004850'], 'URL': 'http://dx.doi.org/10.1016/S1473-3099(21)00485-0', 'relation': {}, 'ISSN': ['1473-3099'], 'subject': ['Infectious Diseases'], 'container-title-short': 'The Lancet Infectious Diseases', 'published': {'date-parts': [[2022, 2]]}, 'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, { 'value': 'Remdesivir plus standard of care versus standard of care alone for the ' 'treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase ' '3, randomised, controlled, open-label trial', 'name': 'articletitle', 'label': 'Article Title'}, { 'value': 'The Lancet Infectious Diseases', 'name': 'journaltitle', 'label': 'Journal Title'}, { 'value': 'https://doi.org/10.1016/S1473-3099(21)00485-0', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, { 'value': 'https://doi.org/10.1016/S1473-3099(21)00559-4', 'name': 'associatedlink', 'label': 'CrossRef DOI link to the associated document'}, {'value': 'article', 'name': 'content_type', 'label': 'Content Type'}, { 'value': '© 2021 Elsevier Ltd. All rights reserved.', 'name': 'copyright', 'label': 'Copyright'}]}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit